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Clinical impact of preexisting vascular calcifications on mortality
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Clinical impact of preexisting vascular calcifications on mortal-
ity after renal transplantation.
Background. Vascular calcifications (VC) are a well-known
cardiovascular risk factor (CVRF) in uremic patients. How-
ever, their role on mortality after renal transplantation (RT)
is unclear.
Methods. In 1117 RT recipients, we investigated the associa-
tion between long-term survival and the presence of VC, eval-
uated by preoperative posteroanterior plain radiography from
aorto-iliac region, at the time of RT. The primary study outcome
was all-cause mortality. Other perioperative CVRF were also
collected.
Results. VC were observed in 273 patients (24.4%) before
RT; additionally, 132 (12%) patients died during follow-up, due,
mainly, to cardiovascular (39%) or infectious (24%) complica-
tions. As expected, patients with VC showed a higher age and
a greater number of CVRF than those without VC. Overall
mortality rate was also higher in VC group (19 vs. 9.5%; P =
0.0001), as well as cardiovascular mortality (9.5 vs. 3.1; P =
0.048). Multivariate Cox model showed that VC were predictor
of overall mortality [relative risk (RR) 1.8; 95% CI 1.1–2.8; P =
0.015] and cardiovascular mortality (RR 2.6; 95%CI 1.1–6); P =
0.033), independently of other CVRF. An interaction between
the presence of VC and diabetes was found. The effect of VC
on mortality was evident in nondiabetic patients, that is, those
with VC had a significantly higher mortality rate than patients
without VC (21 vs. 9%; P = 0.0001). By contrast, these differ-
ences were not observed in diabetic patients (16.5 vs. 14.3%;
P = 0.656).
Conclusion. VC evaluated by a simple and inexpensive plain
radiography are an independent predictor of cardiovascular and
all-cause mortality following RT. This finding may encourage
the implementation of appropriate therapeutic strategies after
RT.
Vascular calcifications (VC) are frequent among long-
term dialysis patients, and this complication by itself
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is an important predictor of all-cause and cardiovas-
cular mortality in this population [1]. Although the
pathogenic mechanisms are not well known, derange-
ment of the calcium/phosphate balance may contribute to
the development of this process, especially medial artery
calcifications [2, 3]. In addition, previous studies have
demonstrated that linear artery calcifications, evaluated
by conventional radiographic films, are strong predictors
of mortality in both general population and uremic pa-
tients [4–6].
Cardiovascular disease (CVD) is prominent in renal
transplant recipients. Nearly half of deaths in this popula-
tion are attributed to CVD [7]. Because this phenomenon
is not sufficiently explained by an increased prevalence
of traditional risk factors in this population [8], we rea-
soned that the presence of preexisting VC may be associ-
ated with an increased risk of all-cause death after renal
transplantation (RT). To date, however, the prognostic
implications of VC following RT remain undetermined.
Thus, the aim of our study was to assess the association
between long-term survival and the presence of VC, as
detected by plain radiography from aorto-iliac region at
the time of RT.
METHODS
Study population
We conducted a retrospective cohort study with 1117
consecutive Caucasian patients who received a cadaveric
kidney between 1981 and 2001 in a regional transplant
center (University Hospital of the Canary Islands, Spain).
Immunosuppression consisted of prednisone plus aza-
thioprine until 1986, and thereafter, prednisone plus anti-
lymphocytic antibodies followed by calcineurin inhibitors
and azathioprine or mycophenolate mofetil.
Data collection
Patient data were collected at the time of transplanta-
tion and during hospitalization until discharge by chart
review. The following data were recorded at the time
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of admission: age, gender, primary kidney disease, dial-
ysis modality, time on dialysis, number of transplan-
tation, human lymphocytic antigen (HLA)-mismatches,
antilymphocytic antibodies, and comorbidity. The latter
was defined as presence or absence of: dyslipidemia,
hepatitis B virus, left ventricular hypertrophy deter-
mined by echocardiographic [9] or electrocardiographic
criteria [10], pretransplant cardiovascular disease (is-
chemic heart disease, heart failure, stroke, and periph-
eral artery disease) defined by standard criteria [11],
obesity (BMI>30 kg/m2), hypertension (blood pressure
>140/90 mm Hg or need for antihypertensive therapy),
and VC evaluated by preoperative conventional radio-
graphs of the aorto-iliac region under standardized con-
ditions. In particular, assessment of arterial calcifications
in the abdominal aorta and iliofemoral axis was estimated
by 2 nephrologists from posteroanterior fine-detail native
radiographs (Eastman Kodak Co., Rochester, NY, USA)
of the abdomen and pelvis performed at the time of RT
as part of our standard clinical practice. Aortic calcifi-
cations were regarded as present if radiodensities were
visible in an area parallel to the lumbar spine. Densi-
ties overlapping the vertebrae were deemed as present
only if they formed a continuity pattern with iliac arter-
ies. Only linear calcifications of aorta, iliac and femoral
arteries, with or without patchy calcifications, were con-
sidered as VC. Isolated patchy calcifications, which may
be associated with intimal calcifications, were not consid-
ered because they could be confounded with other types
of extravascular calcifications as phleboliths. As previ-
ously described, VC were qualitatively determined as
absent (score = 0) or present (score = 1) in whichever
of the studied zones [12]. Finally, VC were only consid-
ered when they were ascertained by both nephrologists
without knowledge of any prevalent or incident clinical
vascular disease. Discordances (<5%) were evaluated by
an independent observer (radiologist) blinded to clinical
data, and the samples therefore were classified correctly
before final analysis.
We also collected the following data: acute tubular
necrosis, acute rejection, and renal function at discharge
expressed as serum creatinine (Scr). Additionally, we also
recorded immunosuppressants at discharge: antilympho-
cytic antibodies, anticalcineurin inhibitors, and azathio-
prine or mycophenolate mofetil.
Outcome
All-cause and cardiovascular mortality were the study
outcome. During the period of follow-up, all deaths were
accurately recorded. Survival was measured in months
from the date of hospital discharge (zero time) to the date
of death. Cardiovascular mortality included death asso-
ciated with a definite myocardial infarction, heart failure,
stroke, arrhythmia, and peripheral vascular accident, all
of which were defined according to standard clinical cri-
teria, and sudden death, which was defined as unexpected
death within 1 hour from the symptom onset and without
any prior condition that would appear fatal [13].
Medical record review was performed according to
Spanish law with reference to clinical data confidentiality
protection. This study was approved by the Ethics Com-
mittee of the University Hospital of the Canary Islands,
and was conducted in accordance with the provisions of
the Declaration of Helsinki.
Statistical analyses
Continuous data were summarized as mean ± SD.
Comparisons of continuous variables between patients
with and without VC were performed using unpaired
t test. Categorical data were compared using chi-square
test. Cox proportional hazards model was used to iden-
tify baseline risk factors for all-cause and cardiovascu-
lar mortality. We included covariates potentially unique
to transplant recipients along with traditional risk fac-
tors. From the time of RT the following variables were
included: recipient and donor age, gender, cause of
renal disease, type of dialysis, body mass index, pre-
transplant cardiovascular disease, vascular calcification,
cardiac hypertrophy, hepatitis B, hepatitis C, dyslipi-
demia, hypertension, retransplant, cold ischemia time,
HLA-mismatches, peak panel-reactive antibodies, and
time on dialysis. The latter was expressed as dichotomous
variable (greater or lesser than 48 months) because only
waiting time >48 months was a significant predictor of
mortality during follow-up when using several categories
for duration on dialysis (<12 months, 12–24 months, 24–
36 months, 36–48 months, and >48 months) in an uni-
variate Cox analysis of our data (P = 0.019). Other
transplant-related factors included in the model were:
acute tubular necrosis, acute rejection, renal function at
discharge, transplant era (1981–1990 vs.1991–2001), and
immunosuppressants at discharge. This analysis was per-
formed with a backward elimination procedure, and the
final Cox model was built observing the rule that no more
than 1 covariate per 10 events should be used in mul-
tivariate models. We also examined the validity of the
proportionality assumption by testing for significance of
covariate-time interaction terms. Covariates included in
the Cox proportional hazards analysis did not violate the
proportionality assumption. We also determined the in-
teraction between VC and diabetes by introducing a cross
product of the 2 dichotomous variables in the Cox regres-
sion analyses for all-cause mortality. Survival analysis was
performed using Kaplan-Meier method and log-rank test
according to the presence or not of VC.
Statistical analyses were performed with SPSS software
version 12.0 (SPSS, Inc., Chicago, IL, USA). A P value
less than 0.05 was considered significant.
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(N = 273) (N = 844) P value
Pretransplantation
Age years 51.3 ± 11.7 40 ± 14 0.000
Male gender % 70 66 0.324
Modality dialysis %
Hemodialysis 85.6 85.3 0.897
Peritoneal dialysis 14.4 14.7
Time on dialysis >48 months % 15.8 15.3 0.853
Diabetes% 49 10 0.000
BMI >30 kg/m2% 9 6.4 0.308
Dyslipidemia % 36 18 0.000




LVH % 64 42 0.000
Retransplant % 10 10.3 0.909
Maximal antibodies % 12 ± 25 10 ± 21 0.347
Post-transplantation




Serum creatinine at discharge
>2 mg/dL %
23.4 27.3 0.248
Mean follow-up months 47 ± 36 65 ± 55 0.000
Conversion factors to SI units: 88.4 (lmol/L).
RESULTS
Among the 1117 patients included in the study, 273
(24.4%) showed VC prior to RT. Baseline clinical and de-
mographic characteristics of the patients with and with-
out VC appear in Table 1. As expected, patients with
VC were older and showed a higher proportion of pre-
transplant diabetes, dyslipidemia, hypertension, and car-
diovascular diseases than those without VC. In addition,
patients with VC showed a lower rate of acute rejection
during admission (Table 1), but renal function was similar
between patients with and without VC at 1 and 5 years
after RT (data not shown).
Median follow-up at the time of this analysis (De-
cember 31, 2002) was 49 months (interquartile range,
15 to 93 months). One hundred and thirty-two (12%)
patients died during follow-up, due, mainly, to cardio-
vascular (39%) and infectious (24%) complications. As
shown in Table 2, patients with VC showed a higher over-
all mortality rate than patients without VC (19 vs. 9.5%;
P = 0.0001). Likewise, 9.5% of patients with VC versus
3.1% of patients without VC died from cardiovascular
causes (P = 0.048). Kaplan-Meier curves revealed signif-
icant survival differences between both groups (Fig. 1A
and B). As an example, the overall 5-year survival was
77% and 91% for patients with and without VC, respec-
tively (log-rank-test; P = 0.00001; Fig. 1A). Similarly, the
5-year cardiovascular mortality was 14% and 3% for pa-
tients with and without VC, respectively (Fig. 1B; P =
0.0001).
Table 2. Causes of death in study patientsa
Patients Patients
Total with VC without VC
Cause of death (N = 1117) (N = 273) (N = 844)
Cardiovascular diseaseb 52 (4.6) 26 (9.5) 26 (3.1)c
Infection 32 (2.8) 10 (3.6) 22 (2.6)
Tumor 17 (1.5) 5 (1.8) 12 (1.1)
Liver disease 7 (0.6) 4 (1.4) 3 (0.3)
Miscellaneous 24 (2.4) 7 (3.6) 17 (2)
Total 132 (11.8) 52 (19) 80 (9.5)d
VC, vascular calcification.
aExpressed as number (%).
bCauses of death from cardiovascular disease include myocardial infarction,
heart failure, stroke, arrhythmia, peripheral vascular accident, and sudden death.
cP = 0.048 and dP = 0.0001 vs. patients with VC.
The effects of independent risk predictors for all-cause
and cardiovascular mortality, using multivariate Cox re-
gression analysis, are shown in Table 3. VC was predic-
tive of greater all-cause mortality [relative risk (RR), 1.8;
95%CI 1.1 to 2.8; P = 0.015] and cardiovascular deaths
(RR, 2.6; 95% CI, 1.1 to 6; P = 0.033) independently of
age, renal function at discharge, diabetes mellitus prior
to RT, obesity, time on dialysis, and pretransplant cardio-
vascular disease (Table 3).
Figure 2 illustrates the result of a significant interaction
between VC and diabetes prior to RT, as calculated by
the Cox regression analysis. In particular, the effect of
VC on mortality was restricted to nondiabetic patients,
that is, those with VC had a significantly higher mortality
rate than patients without VC (21 vs. 9%; P = 0.0001). By
contrast, these differences were not observed in diabetic
patients (16.5 vs. 14.3%; P = 0.656).
DISCUSSION
This cohort study demonstrates for the first time that
VC, evaluated by plain radiography, are a strong and in-
dependent predictor of long-term all-cause mortality and
cardiovascular deaths in RT recipients. Additionally, the
effect of VC on mortality was more pronounced in non-
diabetic patients. This finding may encourage the imple-
mentation of appropriate therapeutic strategies after RT
in order to reduce long-term mortality.
Arterial calcifications may develop at 2 places in the
arterial wall: the intima and the media [5, 14]. Intimal
calcifications have been easily differentiated from medial
calcification by plain radiography. In particular, linear cal-
cification corresponds to medial calcification, previously
described as railroad calcifications [15]. While intimal cal-
cification can compromise blood flow, leading to tissue
ischemia and necrosis, linear calcification is associated
with arterial stiffening and reduced vascular compliance.
These calcification patterns have been related to adverse
clinical outcome in both general population [4, 16] and
uremic patients [6, 12]. In this respect, London et al [5]
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0 12 24 36 48 60 72 84 96
Patients without VC
Number at risk
635 542 475 422 367 324 275 225
Patients with VC 187 160 137 121 86 63 44 33
Months
Log-rank test = 32
P = 0.00001
B
Fig. 1. Kaplan-Meier analysis of (A) overall survival and (B) cardio-
vascular event-free survival of 1117 patients with and without vascular
calcifications (log-rank analysis: P = 0.00001). Dotted line = patients
without VC; gray line = patients with VC. Numbers at the bottom refer
to patients at risk entering each 12-month interval.
recently demonstrated that both intimal and medial cal-
cification are strong predictors of death in hemodialysis
patients. However, to our knowledge this had not been
previously investigated in RT population.
CVD is the major cause of death in RT recipients [7,
8]. Because post-transplant CVD mortality is not largely
explained by increased prevalence of traditional risk fac-
tors, a significant role of other nonmodifiable prognostic
factors such as VC appears likely. Our results are consis-
tent with this reasoning. VC, assessed by means of preop-
erative plain radiography, were an important risk factor
of mortality in RT recipients, regardless of other tradi-
tional risk factors. The Cox proportional analysis was
used to estimate the independent contribution of VC
on mortality while controlling for relevant risk factors.
We only considered linear calcifications, with or without
patchy calcifications. Both calcification patterns (intimal
and medial) may coexist in the same patient, contribut-
ing to a poor prognosis [5]. Our VC assessment, thus,
does not exclude association of intimal and medial calci-
fication, which could explain the strong relationship be-
tween VC and long-term survival in our patients. In a
previous report, similar assessment of VC was also as-
sociated with cardiovascular mortality in hemodialysis
patients [6]. Consequently, this inexpensive and readily
available radiologic method may be a useful tool to iden-
tify RT recipients at higher cardiovascular risk. Although
more sensitive methods (helical or electron-beam com-
puted tomography) provide more detailed information
about the extension of VC in arterial beds [18–20], they
are more sophisticated and require high time consuming
and experienced personnel. Additionally, the image res-
olution of these techniques is insufficient to distinguish
between intimal and medial calcifications. In fact, the re-
cent KDOQI clinical practice guidelines include the use
of plain radiographic films of bone for VC assessment
[21]. Further comparative investigations of different tech-
niques are needed.
VC are now considered an interesting predictive tool
for the assessment of atherosclerotic disease. More-
over, VC has been described as a late inflamma-
tory phenomenon in response to lipid oxidation and
macrophage infiltration after initial plaque formation in
the atherosclerotic process [1]. Medial calcification may
also occur with or without intimal lesions. These may lead
to arterial stiffening. In addition, chronic inflammation
may contribute to both forms of calcifications. Taken to-
gether, these factors could explain a higher all-cause and
cardiovascular mortality in our patients with VC, as pre-
viously suggested [1, 5, 17].
Because accelerated atherosclerosis is the main com-
plication of diabetes, we investigated an interaction be-
tween this disorder and VC. Interestingly, we found that
the hazard effect of VC was restricted to nondiabetic pa-
tients. There are several possible reasons for these re-
sults. Of the multiple risk factors analyzed, only a higher
age and a longer duration of dialysis were observed in
calcified nondiabetic patients compared with diabetic re-
cipients (data not shown), which are strong predictors of
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Table 3. Risk factors for all-cause mortality and cardiovascular mortality in 1117 patients following renal transplantationa
All-cause mortality Cardiovascular mortality
N = 132 N = 52
Relative riskb Relative riskb
Variable (95% CI) P value (95% CI) P value
Age years
<40 (41.2) Reference Reference
40–60 (47.1) 1.6 (1.1–2.5) 0.030 1.6 (0.7–3.6) 0.239
>60 (11.7) 3.2 (1.8–5.7) 0.000 3.5 (1.3–9.5) 0.015
Scr >2 mg/dL at discharge (24.7) 1.7 (1.1–2.5) 0.007 5.2 (2.4–11) 0.000
Diabetes prior RT (19.4) 1.7 (1.1–2.8) 0.047 2.8 (1.1–7.1) 0.029
BMI >30 kg/m2 (4.4) 2.4 (1.1–5.4) 0.037 4.3 (1.1–16) 0.032
Vascular calcifications (24.4) 1.8 (1.1–2.8) 0.015 2.6 (1.1–6) 0.033
Time on dialysis >48 months (18) 1.6 (1.1–2.5) 0.023 2.2 (1–4.7) 0.040
Pretransplant cardiovascular disease (19)c 1.7 (1.1–2.6) 0.018 3.1 (1.5–6.3) 0.003
Abbreviations are: BMI, body mass index; Scr, serum creatinine; RT, renal transplantation. Conversion factors to SI units: creatinine 88.4 (lmol/L).
aCox proportional-hazard model.
bAdjusted for all risk factors listed in the table. In parentheses are shown the percentage of patients having the characteristics indicated by that variable. A relative
risk greater or less than 1.00 indicates a higher or lower risk for death, respectively. Included in the model, but not in the table, were male gender, cardiac hypertrophy,
number of transplant, type of dialysis, retransplant, cold ischemia time, donor age, transplant era (1981–1990 versus 1991–2001), hepatitis, B, hepatitis C, dyslipidemia,
hypertension, acute rejection, peak panel-reactive antibodies, and immunosuppressants at discharge (each with P > 0.5).
cPretransplant cardiovascular disease includes: ischemic heart disease, heart failure, stroke, and peripheral artery disease.
death after RT [22]. Alternatively, it is well known that
established cardiovascular risk factors are more preva-
lent in diabetic than nondiabetic patients, affecting pro-
foundly the pathogenesis of atherosclerosis. Moreover,
VC are more severe in diabetic patients than nondiabetic
population [23]. Thus, it is plausible that the effect of VC
on mortality could have been obscured by diabetes per
se among our diabetic recipients.
VC are a common complication of chronic kidney dis-
ease. In uremic patients the prevalence of arterial calci-
fications increases with age, presence of diabetes, higher
dose of calcium-based phosphate binders, and duration
of dialysis, among others [24]. Waiting time on dialysis
has been also associated with worse outcome after RT
[22]. Accordingly, our patients with VC at the time of
RT showed a higher age and a greater proportion of di-
abetes prior to RT than those without VC. In addition, a
longer time on dilaysis was an independent risk predictor
for mortality. Although successful RT may improve some
risk factors associated with uremic state, these results sug-
gest that VC may extend or, at least, do not regress in a
considerable proportion of renal transplant recipients, as
recently reported [25]. In this respect, inherent factors to
RT may contribute to the development of VC by increas-
ing traditional risk factors or up-regulating specific genes
and transcription factors in the active process of calcifi-
cation. Future longitudinal studies are needed to clarify
these aspects.
Patients with VC showed a lower rate of acute rejec-
tion. Similarly, diabetic patients also had less acute re-
jections during admission than patients without diabetes
(data not shown). Why such patients with vascular dis-
ease have a reduced risk of immunologic dysfunction is


















Fig. 2. Percentage of death in nondiabetic and diabetic patients ac-
cording to the presence or absence of VC. In brackets are shown the
mean time of follow-up in months of patients with or without diabetes
prior to RT. ∗P = 0.0001 vs. non-VC. VC, vascular calcifications.
The principal limitation of this study is that we did not
record important risk factors of comorbidity emerging
during follow-up, such as immunosuppressants changes,
metabolic disorders, renal function during follow-up, or
infections, among others. However, this was consistent
with the study aim, that is, to assess the impact of pre-
existing VC on the prediction of long-term mortality in
incident renal transplant recipients.
CONCLUSION
The results of this study showed that preexisting VC,
evaluated by plain radiographic film from aorto-iliac re-
gion, were by themselves a strong predictor of all-cause
and cardiovascular mortality following RT, especially in
nondiabetic patients. More attention should be focused
on screening for this clinically silent and potentially lethal
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complication in RT recipients in order to optimize future
therapeutic strategies.
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